Other Health

United States Scleroderma Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Friday, September 18, 2020 - 4:36pm

The "US Scleroderma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Scleroderma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • US Scleroderma Market and Competitive Landscape Highlights - 2020, provides comprehensive insights into Scleroderma pipeline products, Scleroderma epidemiology, Scleroderma market valuations and forecast, Scleroderma drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Scleroderma treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Find out how the market advanced from 2016 and forecast to 2025
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Scleroderma products

United States Fibromyalgia Market and Competitive Landscape 2020 - ResearchAndMarkets.com

Friday, September 18, 2020 - 4:20pm

The "US Fibromyalgia Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Fibromyalgia Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • The latest research US Fibromyalgia Market and Competitive Landscape Highlights - 2020, provides comprehensive insights into Fibromyalgia pipeline products, Fibromyalgia epidemiology, Fibromyalgia market valuations and forecast, Fibromyalgia drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Fibromyalgia treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Find out how the market advanced from 2016 and forecast to 2025
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Fibromyalgia products

United States Rheumatoid Arthritis Market and Competitive Landscape Report 2020: Epidemiology, Key Products Marketed, Market Valuations and Forecast, Drugs Sales and Market Shares 2016-2025 - ResearchAndMarkets.com

Friday, September 18, 2020 - 4:09pm

US Rheumatoid Arthritis Market and Competitive Landscape Highlights - 2020, provides comprehensive insights into Rheumatoid Arthritis pipeline products, Rheumatoid Arthritis epidemiology, Rheumatoid Arthritis market valuations and forecast, Rheumatoid Arthritis drugs sales and competitive landscape in the US.

Key Points: 
  • US Rheumatoid Arthritis Market and Competitive Landscape Highlights - 2020, provides comprehensive insights into Rheumatoid Arthritis pipeline products, Rheumatoid Arthritis epidemiology, Rheumatoid Arthritis market valuations and forecast, Rheumatoid Arthritis drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Rheumatoid Arthritis treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Rheumatoid Arthritis pipeline: Find out the products in clinical trials for the treatment of Rheumatoid Arthritis by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Rheumatoid Arthritis drugs: Identify key products marketed and prescribed for Rheumatoid Arthritis in the US, including trade name, molecule name, and company
    Rheumatoid Arthritis market valuations: Find out the market size for Rheumatoid Arthritis drugs in 2019 in the US.
  • Find out how the market advanced from 2016 and forecast to 2025
    Rheumatoid Arthritis drugs market share: Find out the market shares for key Rheumatoid Arthritis drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Rheumatoid Arthritis products

United States Glioma Market and Competitive Landscape Report 2020: Epidemiology, Key Products Marketed, Market Valuations and Forecast, Drugs Sales and Market Shares 2016-2025 - ResearchAndMarkets.com

Friday, September 18, 2020 - 3:47pm

The "US Glioma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Glioma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • US Glioma Market and Competitive Landscape Highlights - 2020, provides comprehensive insights into Glioma pipeline products, Glioma epidemiology, Glioma market valuations and forecast, Glioma drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Glioma treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Find out how the market advanced from 2016 and forecast to 2025
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Glioma products

Kansas City Independent School Deploys Black & Veatch’s Rapid Modular Health System Unit to Combat COVID-19

Friday, September 18, 2020 - 3:00pm

Prioritizing the well-being of its stakeholders amid the COVID-19 pandemic, The Barstow School in suburban Kansas City has deployed Black & Veatchs Rapid Modular Health System (RaMHS) structures to assist with coronavirus screenings of students, faculty and staff.

Key Points: 
  • Prioritizing the well-being of its stakeholders amid the COVID-19 pandemic, The Barstow School in suburban Kansas City has deployed Black & Veatchs Rapid Modular Health System (RaMHS) structures to assist with coronavirus screenings of students, faculty and staff.
  • The RaMHS unit will provide a second location for students to receive daily temperature screenings, making campus arrival and check-in more efficient.
  • The Barstow School is pleased to partner with Black & Veatch to offer the innovative RaMHS unit to our school community, said Shane Foster, president of The Barstow School, which emphasizes science, technology, engineering, math (STEM) and the arts (STEAM).
  • RaMHS modules already have been put to use by a Kansas City-area health system and by the University of Kansas .

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Two Cycles of Chemotherapy as First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

Friday, September 18, 2020 - 12:17pm

Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer and accounts for up to 84% of diagnoses.

Key Points: 
  • Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer and accounts for up to 84% of diagnoses.
  • By harnessing the bodys own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.
  • In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world.
  • OPDIVO (nivolumab), in combination with YERVOY (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic melanoma.

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal

Friday, September 18, 2020 - 11:00am

Data from the POD1UM-202 trial are encouraging and support further investigation of the potential of retifanlimab to become a much needed treatment option for patients with SCAC.

Key Points: 
  • Data from the POD1UM-202 trial are encouraging and support further investigation of the potential of retifanlimab to become a much needed treatment option for patients with SCAC.
  • POD1UM-303/InterAACT 2 (NCT04472429), a Phase 3 trial of retifanlimab in combination with carboplatin and paclitaxel in patients with inoperable locally recurrent or metastatic SCAC is now open and recruiting patients.
  • POD1UM-202 (NCT03597295) is an open-label, single-arm, multicenter, Phase 2 study evaluating retifanlimab in patients with squamous cell carcinoma of the anal canal (SCAC) who have progressed following platinum-based chemotherapy.
  • The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.

Global Healthcare Service Robots Market Analysis and Forecast, 2020-2025: Robots Lending a Hand During Covid-19 Outbreak - ResearchAndMarkets.com

Friday, September 18, 2020 - 9:41am

The "Global Healthcare Service Robots Market: Analysis and Forecast, 2020-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Healthcare Service Robots Market: Analysis and Forecast, 2020-2025" report has been added to ResearchAndMarkets.com's offering.
  • Hence, it is anticipated that these trends will have a significant impact on healthcare service robots market in the next five years, and the market will grow multifold.
  • Global healthcare service robots market is currently witnessing a significant change in the market landscape.
  • What are the major market drivers, challenges, and opportunities in the global healthcare service robots market?

Outset Medical Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Thursday, September 17, 2020 - 9:01pm

Outset Medical, Inc. (Nasdaq: OM) (Outset) today announced the closing of its initial public offering of 10,293,777 shares of its common stock, including the exercise in full by the underwriters option to purchase 1,342,666 additional shares of common stock, at the initial public offering price of $27.00 per share.

Key Points: 
  • Outset Medical, Inc. (Nasdaq: OM) (Outset) today announced the closing of its initial public offering of 10,293,777 shares of its common stock, including the exercise in full by the underwriters option to purchase 1,342,666 additional shares of common stock, at the initial public offering price of $27.00 per share.
  • The gross proceeds to Outset, before deducting underwriting discounts and commissions and offering expenses, were approximately $277.9 million.
  • The shares began trading on The Nasdaq Global Select Market on September 15, 2020, under the symbol "OM."
  • Outset Medical, Inc. is a rapidly growing medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis.

Phibro Animal Health Corporation Announces Chief Financial Officer Changes

Thursday, September 17, 2020 - 9:15pm

Phibro Animal Health Corporation (the Company or Phibro) today announced that Richard Johnson, Phibros Chief Financial Officer, has informed the Company that he will retire from his position effective November 15, 2020, subsequent to the Companys annual meeting and completion of the Companys earnings report for the quarter ending September 30, 2020.

Key Points: 
  • Phibro Animal Health Corporation (the Company or Phibro) today announced that Richard Johnson, Phibros Chief Financial Officer, has informed the Company that he will retire from his position effective November 15, 2020, subsequent to the Companys annual meeting and completion of the Companys earnings report for the quarter ending September 30, 2020.
  • Phibro also announced that Damian Finio will join Phibro on October 26, 2020, and will succeed Mr. Johnson as Phibros Chief Financial Officer, effective November 15, 2020.
  • From November 2015 through January 2018, Mr. Finio served as Chief Financial Officer of Virtus Pharmaceuticals LLC.
  • Phibro Animal Health Corporation is a diversified global developer, manufacturer and supplier of a broad range of animal health and mineral nutrition products for livestock, helping veterinarians and farmers produce healthy, affordable food while using fewer natural resources.